ADVISORY, May 18, 2017 (GLOBE NEWSWIRE) --
argenx (Nasdaq:ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, will visit the Nasdaq MarketSite in Times Square, in celebration of its initial public offering (IPO).
In honor of the occasion, Tim Van Hauwermeiren, Chief Executive Officer, will ring the Opening Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Thursday, May 18, 2017 – 9:15 a.m. to 9:30 a.m. ET
argenx Media Contact:
+32 (0)477 77 29 44
+32 (0)9 310 34 19
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
For photos from ceremonies and events, please visit our Instagram page:
For livestream of ceremonies and events, please visit our YouTube page:
For news tweets, please visit our Twitter page:
For exciting viral content and ceremony photos, please visit our Tumblr page:
A live stream of the Nasdaq Opening Bell will be available at:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody™ Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 89 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11 trillion. To learn more, visit: http://business.nasdaq.com.
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.